Wolfgang E Schmidt
Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity
Otte J, Zdebik A, Brand S, Chromik A, Strauss S, Schmitz F, Steinstraesser L, Schmidt W. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regul Pept 2009; 156:104-17.
Mar 26, 2009Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity
Mar 26, 2009Regul Pept 2009; 156:104-17
Otte Jan-Michel, Zdebik Anna-Elisabeth, Brand Stephan, Chromik Ansgar M, Strauss Sarah, Schmitz Frank, Steinstraesser Lars, Schmidt Wolfgang E
Probiotics regulate the expression of COX-2 in intestinal epithelial cells
Otte J, Mahjurian-Namari R, Brand S, Werner I, Schmidt W, Schmitz F. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr Cancer 2009; 61:103-13.
Jan 1, 2009Probiotics regulate the expression of COX-2 in intestinal epithelial cells
Jan 1, 2009Nutr Cancer 2009; 61:103-13
Otte Jan-Michel, Mahjurian-Namari Rudja, Brand Stephan, Werner Ilka, Schmidt Wolfgang E, Schmitz Frank
Human beta defensin 2 promotes intestinal wound healing in vitro
Otte J, Werner I, Brand S, Chromik A, Schmitz F, Kleine M, Schmidt W. Human beta defensin 2 promotes intestinal wound healing in vitro. J Cell Biochem 2008; 104:2286-97.
Aug 15, 2008Human beta defensin 2 promotes intestinal wound healing in vitro
Aug 15, 2008J Cell Biochem 2008; 104:2286-97
Otte Jan-Michel, Werner Ilka, Brand Stephan, Chromik Ansgar M, Schmitz Frank, Kleine Michael, Schmidt Wolfgang E
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
Berg T, Alshuth U, Martus P, Spengler U, Klinker H, Kallinowski B, Schmidt W, Pape G, Rasenack J, Goeser T, Buggisch P, Gerlach T, Heintges T, Sarrazin C, Nasser S, von Wagner M, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-97.
Apr 1, 2006Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
Apr 1, 2006Gastroenterology 2006; 130:1086-97
Berg Thomas, Alshuth Ulrich, Martus Peter, Spengler Ulrich, Klinker Hartwig, Kallinowski Birgit, Schmidt Wolfgang E, Pape Gerd R, Rasenack Jens, Goeser Tobias, Buggisch Peter, Gerlach Tilman, Heintges Tobias, Sarrazin Christoph, Nasser Samer, von Wagner Michael, Zeuzem Stefan